Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).
Timothy S. Dutill
Advertisement
Timothy S. Dutill is the process development specialist II at the Infections Disease Research Institute
Articles by Timothy S. Dutill
Advertisement
Latest Updated Articles
Characterization of Aluminum Hydroxide Gel and Oil-in-Water Emulsion Formulations Containing CpG ODNsPublished: October 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
2
Op-Ed: Why the US Must Move Beyond Its mRNA Monoculture
3
BioPharm Weekly News Roundup—Week of Nov. 24, 2025
4
What a $2 Billion Maryland Expansion Means for the Future of Biologics Production
5
